HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Saikia, N. Articles by Tandon, R. Search for Related Content PubMed PubMed Citation Articles by Saikia, N. Articles by Tandon, R.

Management of patients with HBeAg-negative chronic hepatitis B

Department of Gastroenterology, Pushpawati Singhania Research Institute, New Delhi, India

Correspondence to:
Correspondence to:
Dr Nripen Saikia
Department of Gastroenterology, Pushpawati Singhania Research Institute, Sheikh Sarai Phase II, Press Enclave Marg, New Delhi 110017, India; saikia.n{at}gmail.com

Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.

Abbreviations: ALT, alanine aminotransferase; CHB, chronic hepatitis B; ETR, end-of-treatment response; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IFN, interferon; PCR, polymerase chain reaction; PEG-IFN, polyethylene glycol moiety attached to interferon; YMDD, tyrosine methionine D-aspartate D-aspartate

Keywords: chronic hepatitis B; HbeAg negative; resistant; entecavir; lamivudine; combination therapy